Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of TAS-115 in Patients with Advanced Solid Tumors.

Next Previous
X
Search
Trial Profile

A Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of TAS-115 in Patients with Advanced Solid Tumors.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 May 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pamufetinib (Primary)
  • Indications Solid tumours
  • Focus First in man; Therapeutic Use
  • Sponsors Taiho Pharmaceutical

    • Most Recent Events

    • 02 Jun 2015 This trial was restarted in December 2013 with a new formulation of TAS 115 (the drug formulation was changed because of the saturation of absorption), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 12 Jan 2015 New source identified and integrated (Japan Pharmaceutical Information Center: JAPIC Clinical Trials Information JapicCTI-111645).
    • 31 Dec 2014 Status changed from recruiting to completed, according to the Japan Pharmaceutical Information Center: JAPIC Clinical Trials Information record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top